Y-Mabs Therapeutics Overview
Latest P/E ratio for Y-Mabs Therapeutics: -44.96 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-44.96
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for YMAB is -44.96. That is below the Healthcare sector average of 25.3. Investors often review this figure alongside Y-Mabs Therapeutics's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, YMAB currently prints -44.96 for P/E ratio, while the sector average sits near 25.3. That is roughly 277.7% below the sector mean. Large gaps often invite a closer look at Y-Mabs Therapeutics's growth, margins, and balance sheet.
A P/E ratio of -44.96 for Y-Mabs Therapeutics is not 'good' or 'bad' on its own. Compare it with the peer average (25.3) and with YMAB's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting YMAB's P/E ratio (-44.96), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Y-Mabs Therapeutics's P/E ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
